Skip to main content

TessArae, Kindstar Developing Genetic Tests for Chinese Population

NEW YORK (GenomeWeb News) – TessArae and Kindstar Global today announced a collaboration to develop genetic tests for the Chinese population.

The two firms provided no details about the test that would be developed except that they will be pan-ethnic screens for the Chinese population and use TessArae's targeted sequencing development platform and bioanalysis software. The tests will run in Kindstar's laboratories in China.

TessArae's platform combines a multiplexed amplification strategy with an Affymetrix microarray protocol. Results are analyzed by the Potomac Fall, Va.-based company's GeneCipher algorithms.

Kindstar is the largest esoteric reference laboratory in China, TessArae said, providing its services to more than 3,300 hospitals. Last week, it and Illumina said they were collaborating to introduce molecular assays based on Illumina products in Kindstar's laboratories.

TessArae and Kindstar did not disclose the financial terms of their deal.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.